Kane Biotech Inc. (TSXV:KNE)
Canada
· Delayed Price · Currency is CAD 0.0350
0.00 (0.00%)
Apr 29, 2026, 9:47 AM EST
Kane Biotech Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 0.43 | 2.08 | 0.15 | 0.16 | 1.61 | Upgrade
|
| Revenue Growth (YoY) | -79.44% | 1296.75% | -4.95% | -90.25% | 19.84% | Upgrade
|
| Cost of Revenue | 0.43 | 1.21 | 0.04 | 0.04 | 1.04 | Upgrade
|
| Gross Profit | -0 | 0.87 | 0.11 | 0.11 | 0.57 | Upgrade
|
| Selling, General & Admin | 1.98 | 3.08 | 2.41 | 2.53 | 4.07 | Upgrade
|
| Research & Development | 0.63 | 1.51 | 1.05 | 1.04 | 1.31 | Upgrade
|
| Operating Expenses | 2.61 | 4.59 | 3.46 | 3.57 | 5.39 | Upgrade
|
| Operating Income | -2.61 | -3.72 | -3.35 | -3.46 | -4.82 | Upgrade
|
| Interest Expense | -0.24 | -0.55 | -1.22 | -0.82 | -0.42 | Upgrade
|
| Interest & Investment Income | 0.02 | 0 | 0.01 | 0.02 | 0.12 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | -0.01 | 0 | -0.02 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -2.83 | -4.27 | -4.56 | -4.28 | -5.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | - | - | - | - | Upgrade
|
| Asset Writedown | -0.04 | -0.21 | -0.01 | - | -0.07 | Upgrade
|
| Other Unusual Items | 0.02 | - | 0 | 0.25 | 0.32 | Upgrade
|
| Pretax Income | -2.83 | -4.47 | -4.56 | -4.02 | -4.85 | Upgrade
|
| Income Tax Expense | -0.11 | -1.31 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -2.72 | -3.16 | -4.56 | -4.02 | -4.85 | Upgrade
|
| Earnings From Discontinued Operations | - | 9.26 | -0.47 | 0.13 | - | Upgrade
|
| Net Income to Company | -2.72 | 6.1 | -5.03 | -3.89 | -4.85 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.25 | Upgrade
|
| Net Income | -2.72 | 6.1 | -5.03 | -3.89 | -4.6 | Upgrade
|
| Net Income to Common | -2.72 | 6.1 | -5.03 | -3.89 | -4.6 | Upgrade
|
| Shares Outstanding (Basic) | 162 | 134 | 127 | 121 | 113 | Upgrade
|
| Shares Outstanding (Diluted) | 162 | 155 | 127 | 121 | 113 | Upgrade
|
| Shares Change (YoY) | 4.40% | 22.23% | 5.32% | 7.20% | 3.67% | Upgrade
|
| EPS (Basic) | -0.02 | 0.05 | -0.04 | -0.03 | -0.04 | Upgrade
|
| EPS (Diluted) | -0.02 | 0.05 | -0.04 | -0.03 | -0.04 | Upgrade
|
| Free Cash Flow | -3.26 | -4.14 | -2.09 | -3.05 | -2.48 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.02 | -0.03 | -0.02 | Upgrade
|
| Gross Margin | -0.15% | 41.91% | 73.48% | 71.48% | 35.36% | Upgrade
|
| Operating Margin | -609.87% | -178.66% | -2248.93% | -2206.05% | -299.63% | Upgrade
|
| Profit Margin | -636.00% | 293.05% | -3379.05% | -2481.86% | -286.39% | Upgrade
|
| Free Cash Flow Margin | -761.99% | -198.77% | -1403.79% | -1947.70% | -153.99% | Upgrade
|
| EBITDA | -2.55 | -3.62 | -3.23 | -3.3 | -4.73 | Upgrade
|
| EBITDA Margin | - | -174.05% | - | - | -294.36% | Upgrade
|
| D&A For EBITDA | 0.06 | 0.1 | 0.12 | 0.16 | 0.08 | Upgrade
|
| EBIT | -2.61 | -3.72 | -3.35 | -3.46 | -4.82 | Upgrade
|
| EBIT Margin | - | -178.66% | - | - | -299.63% | Upgrade
|
| Revenue as Reported | 0.43 | 2.08 | 0.15 | 0.16 | 1.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.